Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.

Matteo PerrinoTommaso De PasSilvia BozzarelliLaura GiordanoFabio De VincenzoFabio ConfortiNunzio DigiacomoNadia CorduaFederica D'AntonioFederica BoreaArmando SantoroPaolo Andrea Zucali

Published in: Cancer (2021)

The primary end point of this study was reached. The high rate of PR (Choi-criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies.

Keyphrases

metastatic colorectal cancer
clinical trial
open label
phase iii
phase ii
radiation therapy
myasthenia gravis
rectal cancer